Date: 2011-02-01
Type of information: Grant
Company: ActoGeniX (Belgium)
Investors: Flemish agency for Innovation by Science and Technology (IWT) (Belgium)
Amount: €0.53 million
Funding type: grant
Planned used: This grant has been awarded to support the discovery and development of a novel ActoBiotic™ for the treatment of Clostridium difficile associated enteric disease. This approach is based on passive immunization through the local enteric delivery of toxins-neutralizing antibodies which are expressed and secreted at the intestinal mucosal site by an ActoBiotic™.
Others: ActoGeniX,has been awarded a € 0.53 million grant ($ 0.7 million) from the Flemish government to support the discovery and development of a novel ActoBiotic™ for the treatment of Clostridium difficile associated enteric disease. This project will be conducted in close collaboration with the world-leading research group of Prof. Dr. Paul Rutgeerts at the University of Leuven, Belgium, and PharmAbs, the antibody research center of the University of Leuven lead by Dr. Nick Geukens. It builds further on the solid expertise ActoGeniX has gained in the field of mucosal delivery of antibodies by orally administered ActoBiotic™. At the forefront of the antibody program is AG014, an ActoBiotic™ secreting a monoclonal antiTNFalpha antibody for the therapy of inflammatory bowel disease which is currently progressing through preclinical development.
Therapeutic area: Infectious diseases